Why partnering with a fully-integrated service provider accelerates drug development | Quotient Sciences

Within the pharmaceutical industry, drug developers are increasingly outsourcing pre-clinical development, clinical research, drug substance manufacturing , and drug product manufacturing to external contract service providers.

Traditionally, the pharmaceutical industry has been structured around functional silos. In a conventional outsourcing approach, a sponsor splits their drug development program between one or more contract development and manufacturing organizations (CDMOs) and a separate contract research organization (CRO).

While this approach can provide benefits including the ability to leverage external expertise and technologies, selecting the right outsourcing partner for a drug development program is an extremely complex process.

Selecting multiple partners only adds to the complexity and time to get new programs up and running. Managing multiple vendors places the project management burden entirely on the sponsor, creates handovers that cause gaps in the project timeline and slow down the drug development process, and limits knowledge and material sharing. All these factors ultimately add to the program’s cost and time to market.

At Quotient Sciences, we have the unique ability to integrate drug substance , drug product, and clinical testing activities for small molecule and peptide therapies under one organization and a single program manager. This is our Translational Pharmaceutics? platform, and it has been used to accelerate the timelines of over 500 drug programs for leading pharma and biotech customers around the world for over 15 years.

Continue reading to learn how the Quotient Sciences Translational Pharmaceutics platform breaks down traditional industry silos to accelerate molecules through development and support customers along the entire drug development pathway, from candidate selection through to commercialization.